Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes

11 Jul 2019

Abstract excerpt

Abstract On the basis of our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this phase II trial, loss of PTEN was a biomarker predictive of response to combined AKT and AR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo pathway signaling and YAP/TAZ
Share to PI3K/AKT/mTOR signaling in cancer
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31296553
DOI: 10.1158/1535-7163.mct-18-1386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target GenesPMID 31296553Read ↗

Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate CancerSemantic proximity Read ↗

TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53 -Mutated Prostate CancerSemantic proximity Read ↗

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionSemantic proximity Read ↗

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancerSemantic proximity Read ↗

Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer.Semantic proximity Read ↗

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancerSemantic proximity Read ↗

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.Semantic proximity Read ↗

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.Semantic proximity Read ↗

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.Semantic proximity Read ↗

The PTEN Conundrum: How to Target PTEN-Deficient Prostate CancerSemantic proximity Read ↗

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerSemantic proximity Read ↗

Oncogenic activation of <i>ERG:</i> A predominant mechanism in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.